Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
Pharmapack Europe recognizes excellence and innovation from exhibitors across connected devices, sustainability, supply chain logistics, route of administration, and packaging innovation, as well from the wider industry for patient-centric design and eco-design
This cost-effective tool will be of immense benefit to other high burden countries as well.
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
The latest certification endorses product for cold chain monitoring across 194 WHO member countries
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Multiples is the first private equity (PE) investor in the company
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
Subscribe To Our Newsletter & Stay Updated
